▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Brian Orelli, PhD

TMFBiologyFool

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Recent Articles by Brian Orelli, PhD

Rabbit Tortoise

Mar 18, 2020 by Brian Orelli, PhD

Johnson & Johnson's Coronavirus Vaccine Won't Be in Clinical Trials Until November

Will slow but steady win the race?

Ventilator

Mar 18, 2020 by Brian Orelli, PhD

U.S. Demand for Ventilators Expected to Surge in Coronavirus Pandemic

Unless the country can slow the pace of COVID-19's spread, the number of people with cases severe enough that they require ventilators to breathe could totally outstrip our supply of the machines.

Scientist in lab

Mar 13, 2020 by Brian Orelli, PhD

Pfizer Outlines Plans to Help With the COVID-19 Outbreak

The pharma giant is helping any way it can.

Mar 13, 2020 by Brian Orelli, PhD

WHO Says There's No Evidence That Pets Can Pass Coronavirus to Humans

But now, the agency isn't so sure about whether people can transmit the disease to dogs and cats.

Coronavirus blood test

Mar 13, 2020 by Brian Orelli, PhD

FDA Issues Emergency Use Authorization for Roche's Coronavirus Test

The test can produce results in under four hours.

Shares down

Mar 12, 2020 by Brian Orelli, PhD

Here's Why NuVasive, Exelixis, and Natus Medical Fell Today

The healthcare companies couldn't sidestep the COVID-19 slump.

Coronavirus blood test

Mar 12, 2020 by Brian Orelli, PhD

Inovio Gets $5 Million From Gates Foundation for a Device to Deliver Its Coronavirus Vaccine

The company hopes to have 1 million doses of its vaccine ready by the end of the year.

Mar 10, 2020 by Brian Orelli, PhD

Here's Why Emergent BioSolutions Jumped Higher on Tuesday

The company added its name to the long list of companies helping develop a vaccine to the coronavirus that causes COVID-19.

Doctor Patient 2

Mar 10, 2020 by Brian Orelli, PhD

Pfizer, GlaxoSmithKline, Johnson & Johnson Team Up on Once-Monthly HIV Treatment

The drug combination has to be injected, but only having to deal with treatment once a month could be worth it for many patients.

Cancer patient and friend

Mar 10, 2020 by Brian Orelli, PhD

Here's Why Compugen Jumped Higher Today

Two patients treated with one of the biotech's drugs had partial responses.

Coronavirus outbreak

Mar 10, 2020 by Brian Orelli, PhD

COVID-19 Nearing Pandemic Level, WHO Warns

The head of the World Health Organization describes the threat of the coronavirus outbreak reaching pandemic proportions as "very real."

Mar 9, 2020 by Brian Orelli, PhD

Here's Why Emergent Biosolutions, BioMarin, and Nuvasive Fell on Monday

Even healthcare companies can't escape the overall market downturn.

Coronavirus outbreak

Mar 9, 2020 by Brian Orelli, PhD

Study Warns Number of U.S. COVID-19 Cases Much Higher Than Reported

Cedars-Sinai researchers say the window to prevent a major epidemic is closing.

Doctor Computer

Mar 9, 2020 by Brian Orelli, PhD

Here's Why Guardant Health Dropped Today

Investors can't figure out how to value this high-growth company.

Coronavirus outbreak

Mar 6, 2020 by Brian Orelli, PhD

Is There a Cure for the SARS-CoV-2 Coronavirus?

Not yet, but multiple drugmakers are working on treatments and vaccines.

Sickle red blood cells

Mar 6, 2020 by Brian Orelli, PhD

Hematology-Focused Biotech Imara to IPO Soon

The company has set terms for its initial public offering.

Accepted stamp

Mar 5, 2020 by Brian Orelli, PhD

BioCryst Looks for FDA Approval in Late 2020, Launches Next Clinical Trial

The FDA is reviewing the biotech's marketing application for its hereditary angioedema treatment berotralstat.

Dentist

Mar 5, 2020 by Brian Orelli, PhD

Align Technology Acquires a Computer-Aided Dentistry Expert

The acquisition moves the Invisalign-focused company further into digital dentistry.

Eye exam

Mar 4, 2020 by Brian Orelli, PhD

Here's Why Shares of Ocular Therapeutix Rocketed Higher Today

Sales of Dextenza are picking up steam, and new data is around the corner.

Woman in a hospital bed

Mar 3, 2020 by Brian Orelli, PhD

Exact Sciences Acquires 2 Cancer Diagnostic Companies

The companies will complement its precision oncology products.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services